12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALX-0171: Phase I started

Ablynx began a placebo-controlled, dose-escalation Phase I trial evaluating ALX-0171. The trial will enroll 44 healthy volunteers in the single-dose portion, followed by about...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >